Francesco Latrofa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7322937/publications.pdf

Version: 2024-02-01

61 2,713 30 51 papers citations h-index g-index

66 66 2306
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens. Annals of Internal Medicine, 2003, 139, 346.	2.0	307
2	Subacute Thyroiditis After Sars-COV-2 Infection. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2367-2370.	1.8	283
3	The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. Journal of Clinical Investigation, 2003, 111, 1897-1904.	3.9	178
4	Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3742-e3746.	1.8	132
5	The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. Journal of Clinical Investigation, 2003, 111, 1897-1904.	3.9	130
6	Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. Journal of Clinical Investigation, 2002, 110, 209-217.	3.9	95
7	Spontaneous Improvement of Untreated Mild Graves' Ophthalmopathy: Rundle's Curve Revisited. Thyroid, 2014, 24, 60-66.	2.4	88
8	Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. Journal of Clinical Investigation, 2002, 110, 209-217.	3.9	75
9	Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 591-596.	1.8	74
10	Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?. Frontiers in Endocrinology, 2018, 9, 314.	1.5	66
11	Outcome of Graves' Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E44-E48.	1.8	62
12	lodine Contributes to Thyroid Autoimmunity in Humans by Unmasking a Cryptic Epitope on Thyroglobulin. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1768-E1774.	1.8	62
13	Lymphocytic Thyroiditis on Histology Correlates with Serum Thyroglobulin Autoantibodies in Patients with Papillary Thyroid Carcinoma: Impact on Detection of Serum Thyroglobulin. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2380-2387.	1.8	61
14	Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy. Thyroid, 2017, 27, 271-278.	2.4	53
15	Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. JAMA Ophthalmology, 2018, 136, 613.	1.4	52
16	Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. European Thyroid Journal, 2019, 8, 192-195.	1.2	49
17	Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study. European Journal of Endocrinology, 2015, 172, 269-276.	1.9	48
18	Evidence that Shed Thyrotropin Receptor A Subunits Drive Affinity Maturation of Autoantibodies Causing Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 927-935.	1.8	47

#	Article	IF	CITATIONS
19	Thyroglobulin Autoantibodies in Patients with Papillary Thyroid Carcinoma: Comparison of Different Assays and Evaluation of Causes of Discrepancies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3974-3982.	1.8	47
20	The Large Majority of 1520 Patients With Indeterminate Thyroid Nodule at Cytology Have a Favorable Outcome, and a Clinical Risk Score Has a High Negative Predictive Value for a More Cumbersome Cancer Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3700-3707.	1.8	47
21	Rehabilitative Orbital Decompression for Graves' Orbitopathy: Risk Factors Influencing the New Onset of Diplopia in Primary Gaze, Outcome, and Patients' Satisfaction. Thyroid, 2012, 22, 1170-1175.	2.4	46
22	Affinity-Enrichment of Thyrotropin Receptor Autoantibodies from Graves' Patients and Normal Individuals Provides Insight into Their Properties and Possible Origin from Natural Antibodies. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4734-4745.	1.8	41
23	Role of the Underlying Thyroid Disease on the Phenotype of Graves' Orbitopathy in a Tertiary Referral Center. Thyroid, 2015, 25, 347-351.	2.4	38
24	lodine, Thyroid Autoimmunity and Cancer. European Thyroid Journal, 2015, 4, 26-35.	1.2	38
25	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without ¹³¹ I Ablation. Thyroid, 2018, 28, 871-879.	2.4	35
26	Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.2	35
27	Low Elasticity of Thyroid Nodules on Ultrasound Elastography Is Correlated with Malignancy, Degree of Fibrosis, and High Expression of Galectin-3 and Fibronectin-1. Thyroid, 2017, 27, 103-110.	2.4	34
28	Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy. Thyroid, 2015, 25, 846-850.	2.4	32
29	Significance of Low Levels of Thyroglobulin Autoantibodies Associated with Undetectable Thyroglobulin After Thyroidectomy for Differentiated Thyroid Carcinoma. Thyroid, 2016, 26, 798-806.	2.4	32
30	An update on the medical treatment of Graves' hyperthyroidism. Journal of Endocrinological Investigation, 2014, 37, 1041-1048.	1.8	31
31	Thyroglobulin-Thyroperoxidase Autoantibodies Are Polyreactive, Not Bispecific: Analysis Using Human Monoclonal Autoantibodies. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 371-378.	1.8	30
32	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1581-1588.	1.8	27
33	Human Monoclonal Thyroglobulin Autoantibodies: Epitopes and Immunoglobulin Genes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5116-5123.	1.8	25
34	Subacute Thyroiditis During the SARS-CoV-2 Pandemic. Journal of the Endocrine Society, 2021, 5, bvab130.	0.1	25
35	Enalapril Reduces Proliferation and Hyaluronic Acid Release in Orbital Fibroblasts. Thyroid, 2013, 23, 92-96.	2.4	21
36	Serum Antibodies against Megalin (GP330) in Patients with Autoimmune Thyroiditis1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2468-2474.	1.8	20

#	Article	IF	Citations
37	Thyroid Volume and Severity of Graves' Orbitopathy. Thyroid, 2013, 23, 97-102.	2.4	20
38	The Detection of Serum IgMs to Thyroglobulin in Subacute Thyroiditis Suggests a Protective Role of IgMs in Thyroid Autoimmunity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2261-e2270.	1.8	20
39	Circulating Thyroglobulin Transcytosed by Thyroid Cells Is Complexed with Secretory Components of Its Endocytic Receptor Megalin*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3458-3467.	1.8	18
40	Thyroid Stimulation Does Not Require Antibodies with Identical Epitopes But Does Involve Recognition of a Critical Conformation at the N Terminus of the Thyrotropin Receptor A-Subunit. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1788-1793.	1.8	18
41	Characterization of thyroglobulin epitopes in Sardinian adults and juveniles with Hashimoto's thyroiditis: evidence against a major effect of age and genetic background on Bâ€cell epitopes. Clinical Endocrinology, 2010, 73, 110-113.	1.2	18
42	Effect of Thyroglobulin Autoantibodies on the Metabolic Clearance of Serum Thyroglobulin. Thyroid, 2018, 28, 288-294.	2.4	18
43	Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves' disease. Autoimmunity Highlights, 2018, 9, 3.	3.9	18
44	Does Graves' Orbitopathy Ever Disappear Answers to an Old Question. European Thyroid Journal, 2017, 6, 263-270.	1.2	16
45	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2520-2526.	1.8	15
46	The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors. Scientific Reports, 2019, 9, 4390.	1.6	12
47	Evidence That the Thyrotropin Receptor Protease is Membrane-Associated and is Not Within Lipid Rafts. Thyroid, 2004, 14, 801-805.	2.4	9
48	Variables Affecting the Long-Term Outcome of Graves Orbitopathy Following High-Dose Intravenous Glucocorticoid Pulse Therapy in Patients not Treated with Orbital Radiotherapy. Endocrine Practice, 2016, 22, 1177-1186.	1.1	9
49	Patients with chronic autoimmune thyroiditis are not at higher risk for developing clinically overt thyroid cancer: a 10-year follow-up study. European Journal of Endocrinology, 2020, 183, 317-323.	1.9	9
50	Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis. European Thyroid Journal, 2021, 10, 237-247.	1.2	7
51	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2845-e2852.	1.8	7
52	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. Thyroid, 2018, 28, 1318-1324.	2.4	6
53	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. Frontiers in Endocrinology, 2018, 9, 590.	1.5	5
54	Autoimmune Hypothyroidism., 2007,, 137-176.		4

#	Article	IF	CITATIONS
55	Optic Neuropathy in 2 Thyroidectomized Patients with Moderate to Severe Graves Ophthalmopathy Following L-Thyroxine Withdrawal Prior to Radioiodine Treatment for Thyroid Carcinoma. AACE Clinical Case Reports, 2015, 1, e119-e122.	0.4	4
56	Over Hypothyroidism in a Woman Undergoing Controlled Ovarian Hyperstimulation. Endocrine Practice, 2014, 20, e11-e13.	1.1	3
57	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. Frontiers in Oncology, 2019, 9, 1390.	1.3	3
58	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, bvab093.	0.1	3
59	Diffuse and Nodular Goiter. , 2012, , 9-48.		2
60	Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade. European Thyroid Journal, 2022, 11 , .	1.2	2
61	A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. Molecular and Clinical Oncology, 2018, 8, 449-452.	0.4	O